{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-107740","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.986969+00:00","generated_at":"2026-05-17T00:01:56.686314+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Structure Therapeutics reports Q3 net loss $65.7M; aleniglipron data on track for year-end 2025","bullets":["Net loss of $65.7M in Q3 2025 vs. $34.0M in Q3 2024; R&D expenses rose to $59.0M from $32.6M.","Cash, cash equivalents and short-term investments totaled $799.0M as of Sep 30, 2025, expected to fund operations through at least 2027.","Topline 36-week data from aleniglipron ACCESS and ACCESS II Phase 2 studies expected by year-end 2025.","Phase 1 study of oral amylin receptor agonist ACCG-2671 anticipated by year-end 2025; second amylin candidate ACCG-3535 declared.","GAAP net loss per share not disclosed; non-cash share-based compensation was $7.5M in Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-107740","json":"https://secwatch.observer/filing/0001104659-25-107740.json","markdown":"https://secwatch.observer/filing/0001104659-25-107740.md","text":"https://secwatch.observer/filing/0001104659-25-107740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465925107740/0001104659-25-107740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465925107740/tm2530323d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:01:56.686314+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}